A phase Ib/II study of the combination of eprenetapopt and AZA in 45 patients with TP53-mutant myelodysplastic syndromes or AML showed a favorable toxicity profile and led to clinical responses in 71% of patients, including complete responses in 44%. This evidence concerns the gene TP53 and myelodysplastic syndrome.